Topic: mouse locomotion

We have developed a marker-based 3D motion capture system for high-precision quantification of mouse locomotion. In our previous studies, we observed that a low dose of a synthetic agonist of cannabinoid CB1 and CB2 receptors, CP55,940 (0.3 mg/kg), causes a small reduction in general locomotion during open-field exploration, but does not inhibit general locomotion during vertical climbing. However, we observed that it induces significant changes in step kinematics during both tasks, which were more pronounced during climbing.We used adult male C57BL/6 mice in a within-subject, randomized desig